Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Despite high debt from the Horizon Therapeutics acquisition, Amgen shows growth potential through obesity drugs, biosimilars ... we can look at already approved products with growth potential.

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current ...

This was made possible by 10 products posting double-digit ... Another risk to Amgen is the potential that the drugs in its pipeline may not commercially materialize as expected.

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen’s Imdylltra (tarlatamab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with small cell lung cancer (SCLC). The drug has been specifically ...

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Acute Myeloid Leukemia.

In this article, we are going to take a look at where Amgen Inc. (NASDAQ ... but also the possibility of higher tariffs and continued drug pricing reforms. Changes in immigration and leadership ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...